Psoriatic arthritis is a complex and heterogeneous disease with potential 
significant disability and impaired quality of life. Although in the last 
decades new treatment options have led to a better management of this disease, 
there are still significant unmet therapeutic needs. Dual inhibitor antibodies 
target two different cytokines simultaneously, potentially offering a better 
disease control. In psoriatic arthritis, there is evidence for a pathogenic role 
not only of IL-17A but also the structurally homologous IL-17F. It is postulated 
that differential expression of both in several targets of PsA could account for 
disparities in clinical response to IL-17A inhibition alone (such as with 
secukinumab or ixekizumab). Here we review the evidence so far for the use in 
psoriatic arthritis of bimekizumab, the first humanized monoclonal IgG1 antibody 
that selectively neutralizes both IL-17A and IL-17F. A Phase 2b trial reports 
better outcomes over both placebo and IL-17A inhibition alone. Very recently 
encouraging results from open-label extensions with regards to both safety and 
maintenance of response were presented. Phase III trials are ongoing with the 
first results awaited in 2021.